|
1.
|
Breitman TR, Selonick SE and Collins SJ:
Induction of differentiation of the human promyelocytic leukemia
cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA.
77:2936–2940. 1980. View Article : Google Scholar
|
|
2.
|
Breitman TR, Collins SJ and Keene BR:
Terminal differentiation of human promyelocytic leukemic cells in
primary culture in response to retinoic acid. Blood. 57:1000–1004.
1981.PubMed/NCBI
|
|
3.
|
Flynn PJ, Miller WJ, Weisdorf DJ, Arthur
DC, Brunning R and Branda RF: Retinoic acid treatment of acute
promyelocytic leukemia: in vitro and in vivo observations. Blood.
62:1211–1217. 1983.PubMed/NCBI
|
|
4.
|
Huang ME, Ye YC, Chen SR, et al: Use of
all-trans retinoic acid in the treatment of acute
promyelocytic leukemia. Blood. 72:567–572. 1988.
|
|
5.
|
Collins SJ, Robertson KA and Mueller L:
Retinoic acid-induced granulocytic differentiation of HL-60 myeloid
leukemia cells is mediated directly through the retinoic acid
receptor (RAR-alpha). Mol Cell Biol. 10:2154–2163. 1990.PubMed/NCBI
|
|
6.
|
Duprez E, Wagner K, Koch H and Tenen DG:
C/EBPbeta: a major PML-RARA-responsive gene in retinoic
acid-induced differentiation of APL cells. EMBO J. 22:5806–5816.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Matikainen S, Ronni T, Hurme M, Pine R and
Julkunen I: Retinoic acid activates interferon regulatory factor-1
gene expression in myeloid cells. Blood. 88:114–123.
1996.PubMed/NCBI
|
|
8.
|
Bennett MT, Sirrs S, Yeung JK and Smith
CA: Hypercalcemia due to all trans retinoic acid in the
treatment of acute promyelocytic leukemia potentiated by
voriconazole. Leuk Lymphoma. 46:1829–1831. 2005.
|
|
9.
|
Imaizumi M, Suzuki H, Yoshinari M, et al:
Mutations in the E-domain of RAR portion of the PML/RAR chimeric
gene may confer clinical resistance to all-trans retinoic
acid in acute promyelocytic leukemia. Blood. 92:374–382.
1998.PubMed/NCBI
|
|
10.
|
Montesinos P, Bergua JM, Vellenga E, et
al: Differentiation syndrome in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and
anthracycline chemotherapy: characteristics, outcome, and
prognostic factors. Blood. 113:775–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shao W, Benedetti L, Lamph WW, Nervi C and
Miller WH Jr: A retinoid-resistant acute promyelocytic leukemia
subclone expresses a dominant negative PML-RAR alpha mutation.
Blood. 89:4282–4289. 1997.PubMed/NCBI
|
|
12.
|
Lengfelder E, Saussele S, Weisser A,
Büchner T and Hehlmann R: Treatment concepts of acute promyelocytic
leukemia. Crit Rev Oncol Hematol. 56:261–274. 2005. View Article : Google Scholar
|
|
13.
|
Hehner SP, Hofmann TG, Dröge W and Schmitz
ML: The antiinflammatory sesquiterpene lactone parthenolide
inhibits NF-kappa B by targeting the I kappa B kinase complex. J
Immunol. 163:5617–5623. 1999.PubMed/NCBI
|
|
14.
|
Sobota R, Szwed M, Kasza A, Bugno M and
Kordula T: Parthenolide inhibits activation of signal transducers
and activators of transcription (STATs) induced by cytokines of the
IL-6 family. Biochem Biophys Res Commun. 267:329–333. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Oka D, Nishimura K, Shiba M, et al:
Sesquiterpene lactone parthenolide suppresses tumor growth in a
xenograft model of renal cell carcinoma by inhibiting the
activation of NF-kappaB. Int J Cancer. 120:2576–2581. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sohma I, Fujiwara Y, Sugita Y, et al:
Parthenolide, an NF-κB inhibitor, suppresses tumor growth and
enhances response to chemotherapy in gastric cancer. Cancer
Genomics Proteomics. 8:39–47. 2011.
|
|
17.
|
Hoffmann R, von Schwarzenberg K,
López-Antón N, Rudy A, Wanner G, Dirsch VM and Vollmar AM:
Helenalin bypasses Bcl-2-mediated cell death resistance by
inhibiting NF-κB and promoting reactive oxygen species generation.
Biochem Pharmacol. 82:453–463. 2011.PubMed/NCBI
|
|
18.
|
Kassuya CA, Cremoneze A, Barros LF, et al:
Antipyretic and anti-inflammatory properties of the ethanolic
extract, dichloromethane fraction and costunolide from Magnolia
ovata (Magnoliaceae). J Ethnopharmacol. 124:369–376. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lyss G, Knorre A, Schmidt TJ, Pahl HL and
Merfort I: The anti-inflammatory sesquiterpene lactone helenalin
inhibits the transcription factor NF-kappaB by directly targeting
p65. J Biol Chem. 273:33508–33516. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Rasul A, Bao R, Malhi M, Zhao B, Tsuji I,
Li J and Li X: Induction of apoptosis by costunolide in bladder
cancer cells is mediated through ROS generation and mitochondrial
dysfunction. Molecules. 18:1418–1433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ferrari FC, Ferreira LC, Souza MR,
Grabe-Guimarães A, Paula CA, Rezende SA and Saúde-Guimarães DA:
Anti-inflammatory sesquiterpene lactones from Lychnophora
trichocarpha Spreng. (Brazilian Arnica). Phytother Res.
27:384–389. 2013.PubMed/NCBI
|
|
22.
|
Kretschmer N, Rinner B, Stuendl N, et al:
Effect of costunolide and dehydrocostus lactone on cell cycle,
apoptosis, and ABC transporter expression in human soft tissue
sarcoma cells. Planta Med. 78:1749–1756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Piornedo Rdos R, de Souza P, Stefanello
ME, Strapasson RL, Zampronio AR and Kassuya CA: Anti-inflammatory
activity of extracts and 11,13-dihydrozaluzanin C from Gochnatia
polymorpha ssp floccosa trunk bark in mice. J
Ethnopharmacol. 133:1077–1084. 2011.PubMed/NCBI
|
|
24.
|
Collins SJ, Ruscetti FW, Gallagher RE and
Gallo RC: Terminal differentiation of human promyelocytic leukemia
cells induced by dimethyl sulfoxide and other polar compounds. Proc
Natl Acad Sci USA. 75:2458–2462. 1978. View Article : Google Scholar
|
|
25.
|
Tanaka H, Abe E, Miyaura C, Shiina Y and
Suda T: 1 alpha,25-dihydroxyvitamin D3 induces differentiation of
human promyelocytic leukemia cells (HL-60) into
monocytemacrophages, but not into granulocytes. Biochem Biophys Res
Commun. 117:86–92. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Kim SH, Danilenko M and Kim TS:
Differential enhancement of leukaemia cell differentiation without
elevation of intracellular calcium by plant-derived sesquiterpene
lactone compounds. Br J Pharmacol. 155:814–825. 2008. View Article : Google Scholar
|
|
27.
|
Song JH, Kim HJ, Lee CH, Kim SJ, Hwang SY
and Kim TS: Identification of gene expression signatures for
molecular classification in human leukemia cells. Int J Oncol.
29:57–64. 2006.PubMed/NCBI
|
|
28.
|
Pan Y, Chen H, Siu F and Kilberg MS: Amino
acid deprivation and endoplasmic reticulum stress induce expression
of multiple activating transcription factor-3 mRNA species that,
when over-expressed in HepG2 cells, modulate transcription by the
human asparagine synthetase promoter. J Biol Chem. 278:38402–38412.
2003. View Article : Google Scholar
|
|
29.
|
Rousseau J, Gagné V, Labuda M, et al: ATF5
polymorphisms influence ATF function and response to treatment in
children with childhood acute lymphoblastic leukemia. Blood.
118:5883–5890. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kang SN, Kim SH, Chung SW, Lee MH, Kim HJ
and Kim TS: Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced
differentiation of human leukaemia HL-60 cells into monocytes by
parthenolide via inhibition of NF-kappa B activity. Br J Pharmacol.
135:1235–1244. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Gutierrez JA, Pan YX, Koroniak L, Hiratake
J, Kilberg MS and Richards NG: An inhibitor of human asparagine
synthetase suppresses proliferation of an L-asparaginase-resistant
leukemia cell line. Chem Biol. 13:1339–1347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Lorenzi PL, Reinhold WC, Rudelius M, et
al: Asparagine synthetase as a causal, predictive biomarker for
L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther.
5:2613–2623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Clavell LA, Gelber RD, Cohen HJ, et al:
Four-agent induction and intensive asparaginase therapy for
treatment of childhood acute lymphoblastic leukemia. N Engl J Med.
315:657–663. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ortega JA, Nesbit ME Jr, Donaldson MH,
Hittle RE, Weiner J, Karon M and Hammond D: L-Asparaginase,
vincristine, and prednisone for induction of first remission in
acute lymphocytic leukemia. Cancer Res. 37:535–540. 1977.PubMed/NCBI
|
|
35.
|
Hongo S, Sakagami H and Sato T: Decrease
in asparagine synthetase activity during cell differentiation of
mouse and human leukemia cell lines. Leukemia. 4:708–711.
1990.PubMed/NCBI
|
|
36.
|
Hashimoto K, Suzuki F and Sakagami H:
Declined asparagine synthetase mRNA expression and enhanced
sensitivity to asparaginase in HL-60 cells committed to monocytic
differentiation. Anticancer Res. 29:1303–1308. 2009.PubMed/NCBI
|
